1 |
|
2 |
Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis[J]. N Engl J Med, 2016, 375(16): 1532-1543. DOI: 10.1056/NEJMoa1607948.
|
3 |
|
4 |
|
5 |
Nilsson AG, Sundh D, Johansson L, et al. Type 2 diabetes mellitus is associated with better bone microarchitecture but lower bone material strength and poorer physical function in elderly women: a population-based study[J]. J Bone Miner Res, 2017, 32(5):1062-1071. DOI: 10.1002/jbmr.3057.
|
6 |
|
7 |
宋亚波. ADA发布新版糖尿病视网膜病变指南[J]. 中华医学信息导报, 2017, 32(4):7.
|
8 |
|
9 |
|
10 |
|
11 |
Ala M, Jafari RM, Dehpour AR. Diabetes mellitus and osteoporosis correlation: challenges and hopes[J]. Curr Diabetes Rev, 2020, 16(9):984-1001. DOI: 10.2174/1573399816666200324152517.
|
12 |
Mohsin S, Baniyas MM, AlDarmaki RS, et al. An update on therapies for the treatment of diabetes-induced osteoporosis[J]. Expert Opin Biol Ther, 2019, 19(9):937-948. DOI: 10.1080/14712598.2019.1618266.
|
13 |
|
14 |
|
15 |
|
16 |
|
17 |
Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension[J]. Lancet Diabetes Endocrinol, 2017, 5(7):513-523. DOI: 10.1016/S2213-8587(17)30138-9.
|
18 |
|
19 |
|
20 |
|
21 |
|
22 |
|